Neuronetics, Inc.
STIMAbout the company
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Investment snapshot
Positive
2
BUY / PASS
Neutral / negative
1 / 13
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 12 investors flag at least one debt & leverage criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | FAIL · Rank #2570 (Top 83%) | PASS | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | PASS | FAIL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | TTM ended 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-17 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-17 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-17 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-11-04 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Debt & Leverage0% pass✓ 2✗ 13▾
No clean pass — all 12 investors flag at least one debt & leverage criterion
LT Debt vs Net Current AssetsLT Debt $61.8M vs NCA $27.0M✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: 3.30, IC: -1.7x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity3.30✗Lynch< 0.33Cash - Long-term Debt$-39.6M✗LynchPositive preferredLT Debt / Total Assets Change39.14% -> 46.49%✗PiotroskiDecreased YoYCurrent Assets / Current Liabilities2.01✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity3.30✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00xDebt Levels3.30✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-1.7x, D/EBITDA=N/A✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity3.30✗Ackman<= 1.0Negative debt-to-equity (higher means less debt)-3.3008; #3957/4210 (top 94.0%)✗AsnessTop 30% of eligible cross-section - Valuation0% pass✓ 1✗ 27▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio4.3x✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-8.6%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-8.6%, ROC=-185.0%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per Share4.3x✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-37.7%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-15.8%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=4.3x✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic Value✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low104% of trailing low ($1.34)✓Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-17.21%; #4470/6340 (top 70.5%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+0.1395; #4532/6449 (top 70.3%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per ShareN/A (non-positive TBVPS)✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+1.1913; #1587/5247 (top 30.2%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-7.15%; #3106/4519 (top 68.7%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date+2.96%; #2303/6202 (top 37.1%)✗OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy$-36.3M✗BuffettPositive and growingFCF Positive and Growing$-9.6M✗LynchPositive and growingOperating Cash Flow$-20.4M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-14.39%, ROA=-27.55%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-15.8%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive0/10 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-10.0%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency0/10 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-9.6M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-7.15%; #3106/4519 (top 68.7%)✗OshaughnessyTop 10% of eligible cross-section - Profitability6% pass✓ 5✗ 30▾
15 of 16 flag STIM's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)0/11 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)0/11 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-104.4%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-21.1% (latest)✗BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-36.3M✗BuffettPositive and growingEarnings Variance (10-yr CoV)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-123.4%✗Lynch> 15%EBIT / Enterprise Value-8.6%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-8.6%, ROC=-185.0%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-27.55%✗PiotroskiROA > 0ROA Change YoY-31.02% -> -27.55% (delta: +3.47%)✓PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-14.39%, ROA=-27.55%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY72.3% -> 48.5%✗PiotroskiImproved YoYPre-Tax Income / Revenue✗Dreman>= 8%Net Income / Shareholders' Equity-123.4%✗Dreman> 12%Margin of SafetyP/B=4.3x✗PabraiP/B < 1.5 or P/E < 15Return on Equity-140.1% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic Value✗Marks>= 20% below intrinsic valuePositive Net Income Frequency0/10 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-9.4%✗Ackman>= 15%Net Income / Shareholders Equity-123.4%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-42.8% (2023) -> -21.1% (2025)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 72.5% -> 48.5%, operating margin -42.8% -> -21.1%✓SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-17.21%; #4470/6340 (top 70.5%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+61.36%; #452/3702 (top 12.2%)✓AsnessTop 30% of eligible cross-sectionNet income / positive book equity-123.36%; #4687/5226 (top 89.7%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.0352; #2112/5884 (top 35.9%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/10 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Growth13% pass✓ 4✗ 9▾
7 of 8 flag STIM's growth — Graham, Lynch, Dreman +4 more
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: 14.4% vs Rev: 23.0%✓LynchInventory growth < Revenue growthEPS Growth Direction✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency0/10 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth9.4%✓Ackman>= 5%Positive EPS Growth Frequency✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 72.5% -> 48.5%, operating margin -42.8% -> -21.1%✓SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR24.8%✓SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Verdicts13% pass✓ 2✗ 14▾
Split decision: 13 FAIL · 2 PASS · 1 NEUTRAL
Overall verdict✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)✗GreenblattRank #2570✓PiotroskiPASS (F-Score 4)✗DremanFAIL (1/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (2/9)✗TempletonFAIL (3/8)✓SleepPASS (3/6)✗AsnessFAIL (Rank #1674/2370 (Top 70.6%))✗NeffFAIL (1/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked) - Efficiency38% pass✓ 4✗ 7▾
5 of 8 flag STIM's efficiency — Buffett, Greenblatt, Munger +2 more
Current Ratio2.01✓Graham>= 2.0ROIC (3-5 yr avg)-72.0%✗Buffett> 10%ROIC - WACC-82.0%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)-185.0%✗Greenblatt> 25%Current Ratio Change YoY1.86 -> 2.02✓PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.53x -> 1.05x✓PiotroskiImproved YoYCurrent Assets / Current Liabilities2.01✓Dreman> 1.5Return on Invested Capital-14.7%✗Munger> 15%ROIC (high and growing)FY2023: ROIC=-25.8%; FY2024: ROIC=-33.0%; FY2025: ROIC=-28.2%✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROICN/A (non-positive net income)✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/5 years above 12% (latest -28.2%)✗SleepROIC > 12% in a majority of years
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 24.4% of shares last year.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-09-30 2025-10-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: revenue, net income, operating income, gross profit, ebit, interest expense, operating cash flow, depreciation amortization, capex. | Q3 FY 2026 2026-07-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $134.1Mcurrent | -- | -- | -- | $144.8Mest. | $172.6Mest. | $98.9Mest. | $160.3Mest. | $95.3Mest. |
| Revenue | $159.8M↑23% | $42.0M↑13% | $41.6M↑9% | $34.5M↑8% | $149.2M↑99% | $74.9M↑5% | $71.3M↑9% | $65.2M↑18% | $55.3M |
| Operating Income | -$15.0M↑60% | $541.0K↑107% | -$1.5M↑81% | -$9.0M↑18% | -$31.4M↑9% | -$34.6M↓13% | -$30.6M↑13% | -$35.1M↓27% | -$27.6M |
| Net Income | -$23.1M↑48% | -$1.7M↑81% | -$3.4M↑66% | -$10.8M↑15% | -$39.0M↑11% | -$43.7M↓45% | -$30.2M↑19% | -$37.2M↓19% | -$31.2M |
| EPS (Diluted) | -- | $-0.02↑85% | $-0.05↑67% | $-0.16↑24% | $-0.59↑57% | $-1.38↓31% | $-1.05↑24% | $-1.38↓13% | $-1.22 |
| Gross Margin | 50.7% | 52.2%↑14% | 51.1%↑10% | 46.9%↓5% | 48.5%↓33% | 72.3% | 72.5%↓5% | 76.3%↓3% | 78.9% |
| Operating Margin | -9.4%↑68% | 1.3%↑107% | -3.6%↑83% | -26.1%↑24% | -21.1%↑54% | -46.2%↓8% | -42.8%↑20% | -53.8%↓8% | -49.8% |
| ROE | -123.4%↑24% | — | — | — | -174.3%↓10% | -157.8%↓79% | -88.3%↓36% | -65.1%↓78% | -36.6% |
| Total Debt | $61.8M↓6% | $61.8M↓6% | $61.5M↑11% | $61.3M↑11% | $65.8M↑19% | $55.2M↓7% | $59.3M↑65% | $36.0M↑2% | $35.3M |
| Shareholders' Equity | $18.7M↓32% | $18.7M↓32% | $17.9M↓34% | $13.3M↓63% | $22.4M↓19% | $27.7M↓19% | $34.2M↓40% | $57.1M↓33% | $85.2M |
| Current Ratio | 2.01↓11% | 2.01↓11% | 1.88↓7% | 1.67↓32% | 2.02↑8% | 1.86↓61% | 4.73↑59% | 2.98↓59% | 7.34 |
| Debt / Equity | 3.30↑37% | 3.30↑37% | 3.45↑68% | 4.62↑196% | 2.94↑48% | 1.99↑15% | 1.73↑175% | 0.63↑52% | 0.41 |
| Operating Cash Flow | -$8.3M↑72% | $1.2M↑258% | -$1.0M↑71% | -$9.4M↑45% | -$20.4M↑34% | -$31.0M↑3% | -$32.0M↓4% | -$30.7M↓10% | -$28.0M |
| Free Cash Flow | -$9.6M↑69% | $768.0K↑185% | -$1.4M↑62% | -$9.6M↑44% | -$21.2M↑35% | -$32.5M↑6% | -$34.4M↓1% | -$34.0M↓12% | -$30.3M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Medical Equipment
STIM vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALCON INCALC | $35.6B | $74.12 | $10.4B | $980.0M | 4.4% | 0.21 | 13.1% | 2.12 | 2/9 | 1/9 | 3/7 | 0/3 | F-Score 6 | 4/11 |
| KONINKLIJKE PHILIPS NVPHG | $29.7B | $30.34 | $21.0B | $1.1B | 8.2% | 0.64 | 8.0% | 1.32 | 1/9 | 1/9 | 1/7 | 0/3 | F-Score 5 | 3/11 |
| WEST PHARMACEUTICAL SERVICES INCWST | $29.0B | $416.42 | $3.1B | $493.7M | 15.5% | 0.06 | 19.0% | 3.02 | 4/9 | 6/9 | 6/7 | 1/3 | F-Score 7 | 5/11 |
| SMITH & NEPHEW PLCSNN | $13.1B | $31.28 | $6.2B | $625.0M | 11.8% | 0.59 | 12.9% | 2.57 | 2/9 | 0/9 | 1/7 | 0/3 | F-Score 6 | 4/11 |
| MSA Safety IncMSA | $6.7B | $174.17 | $1.9B | $278.9M | 20.4% | 0.42 | 19.8% | 3.01 | 5/9 | 5/9 | 4/7 | 1/3 | F-Score 5 | 7/11 |
| STAAR SURGICAL COSTAA | $1.3B | $26.39 | $239.4M | $80.4M | -23.4% | — | -38.3% | 4.55 | 2/9 | 2/9 | 2/7 | 0/3 | F-Score 3 | 3/11 |
| ARTIVION, INC.AORT | $931.9M | $19.10 | $441.3M | $9.8M | 2.2% | 0.48 | 7.6% | 3.53 | 2/9 | 0/9 | 0/7 | 0/3 | F-Score 7 | 1/11 |
| InMode Ltd.INMD | $763.6M | $13.27 | $370.5M | $93.8M | 13.7% | — | 23.0% | 9.88 | 5/9 | 3/9 | 0/7 | 3/3 | F-Score 4 | 4/11 |